Because the use of prostigmine methylsulfate in the prevention and treatment of various disorders has been reported so favorably and further because in the recent months it has created a furor in the otologic world,1 we began a methodical study of 59 cases, despite the fact that our past results from the employment of prostigmine in the treatment of deafness and tinnitus aurium had been disappointing.
We carefully selected our cases, making certain that in each there was freedom from sinus involvement and from obstruction of the eustachian tube. By so doing, we hoped that our results would be as gratifying as those of our predecessors but unfortunately our report, which follows, shows the contrary.
Prostigmine methylsulfate is described as "the dimethylcarbamic ester of 3-hydroxyphenyltrimethylammonium methylsulfate," with the following structural formula:
It belongs to the group of so-called autonomie drugs, being para-sympatheticomimetic. The great bulk of pharmacologie evidence
ERSNER MS, RUSH IA, MYERS D. PROSTIGMINE METHYLSULFATE IN THE TREATMENT OF DEAFNESS AND TINNITUS AURIUM: REPORT OF FIFTY-NINE CASES WITH NEGATIVE RESULTS. Arch Otolaryngol. 1941;33(2):193–198. doi:10.1001/archotol.1941.00660030196003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: